Extract prepared from the leaves of Ocimum basilicum inhibits the entry of Zika virus.

The recent Zika virus (ZIKV) outbreaks and rapid spread in tropical Latin America since introduction to Brazil in 2014, and now appearing cases in the USA, are alarming. World Health Organization (WHO) has considered transmission of ZIKV, a serious public health problem because of the increasing number of outbreaks. There are currently no drugs approved for the treatment of ZIKV infection. Discovery of safe and effective drugs are hampered by the risk in treating pregnant woman and toxicity to the fetus. Sweet basil, known as Ocimum basilicum in the scientific community, is a very well-known medicinal herb. Numerous studies have documented its beneficial activity against a great variety of human pathogens ranging from bacteria and virus to fungus and protozoans. Although, basil extracts and oils have been tested successfully against other viruses, its application to tackle ZIKV infection has not been exploited at all. In this study, we report for the first time that highly diluted ethanol extracts prepared from basil leaves can effectively inhibit ZIKV replication in Vero E6 cells with a half maximal inhibitory concentration (IC50) value of 1:134. The diluted extract as well as the amount of ethanol that goes into its preparation have been found to be completely non-toxic to the above mentioned cell line. The extract seems to inhibit the virus at the step of attachment and entry into the host cell. The specific inhibition of ZIKV observed using the basil leaf extract suggests a new alternative mode of treatment against flavivirus. Keywords: Zika virus; basil extract; antiviral.

Dexamethasone alone vs in combination with transcutaneous electrical acupoint stimulation or tropisetron for prevention of postoperative nausea and vomiting in gynaecological patients undergoing laparoscopic surgery.

BACKGROUND: Postoperative nausea and vomiting (PONV) is commonly reported after surgery and anaesthesia. We compared the effects of combinations of electrical acupoint stimulation or tropisetron with dexamethasone with the effects of dexamethasone alone, for inhibition of PONV in gynaecological patients undergoing laparoscopic surgery. METHODS: We randomized 157 patients undergoing elective gynaecological laparoscopic surgery under general anaesthesia into the following three groups: acupoint stimulation+dexamethasone (Group Acu, n=53), tropisetron+dexamethasone (Group Trp, n=53), and dexamethasone alone (Group Dxm, n=51). The incidence of nausea, vomiting, and need for rescue antiemetics was recorded 2, 6, 24, and 48 h after surgery. RESULTS: We found significant differences in the incidence of PONV during 24 h after surgery between the combination therapy groups and the dexamethasone-alone group (P=0.021). In the first 24 h, 28% of patients in Group Acu, 26% of patients in Group Trp, and 50% of patients in Group Dxm experienced nausea, vomiting, or both. The incidence of 24 h PONV in Group Acu was significantly lower than that in Group Dxm (P=0.048; odds ratio 0.389; 95% CI 0.170-0.891). The incidence of 24 h PONV in Group Trp was also significantly lower than that in Group Dxm (P=0.042; odds ratio 0.359; 95% CI 0.157-0.819). There was no significant difference between Group Acu and Group Trp (P=0.857). The need for antiemetic rescue medication was similar in the three groups. All groups expressed similar patient satisfaction. CONCLUSIONS: Combined with dexamethasone, electrical acupoint stimulation or tropisetron is more effective in PONV prophylaxis than dexamethasone alone in gynaecological patients undergoing laparoscopic surgery. CLINICAL TRIAL REGISTRATION: NCT 02096835.